Building India's next-generation pharmaceutical CDMO
Biodeal Pharmaceuticals Limited is a high-growth Pharmaceutical CDMO with a proven track record of 20+ years. A ₹110 Crore strategic investment from Piramal Alternatives — followed in 2026 by a further ₹400 Crore+ round from a leading institutional investor — marks a defining inflection point, validating our manufacturing quality, business model, and the expanding global demand for WHO-GMP certified Indian CDMO services.
Capital, and a vote of confidence from one of India's most respected healthcare investors
₹110 Crore Strategic Investment — Piramal Alternatives
Piramal Alternatives is one of India's most respected institutional investors in the healthcare and pharmaceutical sector. Their investment in Biodeal reflects rigorous institutional due diligence across manufacturing quality, regulatory compliance, management capability, and growth potential.
This investment is not merely capital — it is institutional validation of Biodeal's position as a credible, scalable Pharmaceutical CDMO.
Injectable Manufacturing Expansion
Capacity scale-up at Paonta Sahib — addressing growing domestic and international demand for sterile CDMO services.
Nasal Spray CDMO Leadership
Strengthening Biodeal's position as India's leading Nasal Spray CDMO — expanding intranasal drug delivery capabilities and commercial capacity.
R&D Enhancement
Accelerating formulation development in priority verticals — nasal sprays, injectables, nutraceuticals.
Why Biodeal is a compelling opportunity
India's pharmaceutical CDMO sector is experiencing significant structural growth. Global pharmaceutical companies are accelerating 'China+1' and 'India+1' supply chain strategies — seeking WHO-GMP certified Indian CDMOs as resilient, cost-efficient manufacturing partners.
Biodeal sits at the intersection of four of the highest-growth segments in the market — a positioning few mid-scale CDMOs can claim.
Injectable manufacturing
The highest-value, fastest-growing CDMO segment — aseptic and sterile fill-finish demand is outpacing supply across India.
Nasal spray manufacturing
Scarce WHO-GMP certified nasal spray capability in India — a genuine competitive advantage in regulated export markets.
Nutraceutical CDMO
One of India's fastest-growing consumer-healthcare segments — with comprehensive dosage-form capability under one roof.
Export business
WHO-GMP and PIC/S are the regulatory passports for export — an established 80+ country base that the investment is built to scale.
From one unit in the hills, to a global CDMO partner
Twenty years of disciplined, compounding growth — and, backed by Piramal Alternatives' strategic investment, a clear runway to scale capacity and export reach.
Eight reasons the thesis holds
A refined view of the investment case — each thesis point paired with the evidence behind it.
WHO-GMP + PIC/S dual certification
Rare credential for a mid-scale Indian CDMO — unlocks regulated-market exports.
Institutional validation
₹110 Cr from Piramal Alternatives — rigorous healthcare-sector due diligence.
Injectable CDMO growth pillar
Dedicated Paonta Sahib sterile facility — high-demand, high-margin segment.
Nasal spray CDMO leadership
India's leading dedicated nasal spray CDMO — scarcity value and export potential.
Diversified revenue
Four product verticals — Pharmaceuticals, Cosmeceuticals, Nutraceuticals, Herbaceuticals.
Established client base
500+ domestic and international brands — low client-concentration risk.
80+ country export reach
Diversified revenue by geography across six global regions.
DSIR R&D capability
In-house formulation development — enables higher-value co-development contracts.
Governance, on the record
Board composition, committee structure, statutory filings and the policies that govern how Biodeal operates — published in full.
Board and CommitteesBoard + 4 committees
Board of Directors
- Mr. Anurag KumarManaging Director
- Mr. Dev DattDirector
- Mrs. Anchal KumariNon-Executive Director
- Mrs. Noopur JhaNon-Executive & Independent Director
- Mr. Adheesh Chander MalhotraNon-Executive & Independent Director
- Mr. Abhishek JainNominee Director
Audit Committee
- Mrs. Noopur JhaChairperson
- Mr. Adheesh Chander MalhotraMember
- Mr. Anurag KumarMember
Nomination and Remuneration Committee
- Mrs. Noopur JhaChairperson
- Mr. Adheesh Chander MalhotraMember
- Mrs. Anchal KumariMember
Corporate Social Responsibility Committee
- Mr. Anurag KumarChairman
- Mr. Dev DattMember
- Mrs. Noopur JhaMember
Committee for Prevention of Sexual Harassment
- Mrs. Bhawna KhannaPresiding Officer
- Mrs. Preeti TeotiaMember
- Mr. Praveen Kumar SaxenaMember
- Mrs. Nutan SinghExternal Member
Annual Reports5 reports
Financial Statements5 statements
General Information4 contacts
302, Kushal Bazar, 32-33, Nehru Place, New Delhi – 110019
bssdelhi@bigshareonline.comwww.bigshareonline.comGF – 8 & 9, Hans Bhawan 1, Bahadur Shah Zafar Marg, New Delhi – 110022
Investor GrievancesDedicated inbox
Shareholders and investors may write to the dedicated investor relations inbox with any query, complaint or grievance. Every submission is logged and routed to the Company Secretary for resolution.
investor.relations@biodealpharma.comLet's discuss the next phase of growth
Request the investor deck, download our corporate profile, or schedule a business discussion with our team. Our IR contact will route you to the right people.